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Abstract 
A large spectrum of more than 2,000 CFTR mutations have been reported, associated with a 
very diverse clinical phenotype of Cystic Fibrosis (CF). In this work we analyzed the 
spectrum of CFTR mutations in CF and in CF-related disorders. The project specifically aims 
at investigating the following points: 
1) Validation of a new diagnostic screening method xTAG (Luminex; panel of 71 mutations), 
for routine analysis compared to the INNO-LiPA® (Innogenetics; panel of 36 mutations), 
used as a reference. Reproducible and concording results were obtained on the Luminex 
platform from DNA Innogenetics positive samples, using DNA extracted from different 
biological matrices, including blood samples, blood spots from Guthrie cards, chorionic villi 
and amniotic fluid. The new panel significantly increases the detection rate for patients of 
southern European origin. 
2) Study of frequencies of CFTR mutations in central Argentina in the Santa Fe province, 
which has never been characterized. A cohort of 83 patients out of an initial local selection of 
121 was analysed. The results were combined with those of a previous study of the 
neighboring Cordoba province, leading to the proposal of a unique panel of 21 CFTR 
mutations for a first line molecular diagnosis in central Argentina. 
3) Analysis of the effects of mutations in the PRSS1, CFTR or SPINK1 genes on the severity 
of sporadic idiopathic pancreatitis. A retrospective cohort of 68 patients carrying mutations in 
the genes was compared to a paired cohort of age- and sex-matched patients with idiopathic 
pancreatitis and negative genetic testing. Clinical and morphological characteristics of 
patients were taken into account in the analysis. Clinical parameters were similar in the two 
cohorts, except for the age of pancreatic disease onset. A significantly higher occurrence of 
pancreas cancer was observed in the case group, particularly in patients carrying mutations in 
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the CFTR gene. We therefore suggest that CFTR variants present a risk factor for pancreatic 
cancer. 
4) Updating the molecular analysis of the CFTR gene in a cohort of patients with allergic 
bronchopulmonary aspergillosis syndrome (ABPA). Samples from 18 patients previously 
analysed using a panel of 13 mutations and reported in a paper published in 2001 were re-
analysed in 2010 using complete exon sequencing. Compared to the first analysis, 8 cases 
were found carrying one CFTR mutation and 4 with two mutations. The study considerably 
extends previous findings by demonstrating a strong link between ABPA in adults and CFTR 
mutations.   
Altogether, these studies contribute to shed new light on the molecular diagnosis of the CFTR 
gene in CF and in CF-related disorders. 
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Résumé 
Un large spectre de plus de 2000 mutations CFTR ont été associées à un phénotype clinique 
très variable de la mucoviscidose. Dans ce travail, nous avons analysé le spectre des 
mutations du gène CFTR chez des patients atteints de mucoviscidose et dans les troubles 
associés à la mucoviscidose. Le projet vise spécifiquement à étudier les points suivants: 
1) Validation d'une nouvelle méthode de dépistage xTAG (Luminex, panel de 71 mutations), 
pour l'analyse de routine par rapport à l'INNO-LiPA® (Innogenetics, panel de 36 mutations), 
utilisé comme référence. Des résultats reproductibles et concordants ont été obtenus sur la 
plate-forme Luminex à partir d'échantillons ADN Innogenetics positifs utilisant de l'ADN 
extrait de différentes matrices biologiques, y compris des échantillons de sang, des taches de 
sang de cartes Guthrie, des villosités chorioniques et du liquide amniotique. Le nouveau panel 
augmente significativement le taux de détection pour les patients d'origine sud-européenne. 
2) Etude des fréquences des mutations du CFTR dans le centre de l'Argentine, dans la 
province de Santa Fe, qui n'a jamais été caractérisée. Une cohorte de 83 patients sur une 
sélection locale initiale de 121 a été analysée. Les résultats ont été combinés avec ceux d'une 
étude précédente de la province voisine de Cordoba, aboutissant à la proposition d'un panel 
unique de 21 mutations du CFTR pour un diagnostic moléculaire de première ligne au centre 
de l’Argentine. 
3) Analyse des effets des mutations dans les gènes PRSS1, CFTR ou SPINK1 sur la gravité de 
la pancréatite idiopathique sporadique. Une cohorte rétrospective de 68 patients porteurs de 
mutations dans ces gènes a été comparée à une cohorte, pairée pour l'âge et le sexe, de 
patients atteints de pancréatite idiopathique avec des tests génétiques négatifs. Les 
caractéristiques cliniques et morphologiques des patients ont été prises en compte dans 
l'analyse. Les paramètres cliniques étaient similaires dans les deux cohortes, à l'exception de 
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l'âge d'apparition de la maladie pancréatique. Une augmentation significative du cancer du 
pancréas a été observée dans le groupe des patients porteurs de mutations, en particulier dans 
le gène CFTR. Nous suggérons donc que les variants de CFTR présentent un facteur de risque 
pour le cancer du pancréas. 
4) Mise à jour de l'analyse moléculaire du gène CFTR dans une cohorte de patients porteurs 
d'un syndrome d'aspergillose bronchopulmonaire allergique (ABPA). Les échantillons de 18 
patients précédemment analysés à l'aide d'un panel de 13 mutations et rapportés dans un 
article publié en 2001 ont été ré-analysés en 2010 en utilisant le séquençage complet des 
exons. Comparativement à la première analyse, 8 cas ont été trouvés porteurs d'une mutation 
CFTR et 4 de deux mutations. L'étude a considérablement étendu les résultats précédents en 
démontrant une forte relation entre ABPA chez les adultes et mutations du CFTR. 
Au total, ces études contribuent à jeter un éclairage nouveau sur le diagnostic moléculaire du 
gène CFTR dans les cas de patients atteints de mucoviscidose et de syndromes associés à la 
mucoviscidose. 
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Introduction 
1. Historical overview 
In the 18th century, the adage that said "Woe to that child which kissed on the forehead tastes 
salty. He is bewitched and will soon die." was an early reference describing the fatal disease 
nowadays known as Cystic Fibrosis (CF). 
During the last century, broad knowledge was progressively acquired to better characterize 
the disease and to understand its pathophysiology. The medical literature of the disease started 
in 1936 when Guido Fanconi, a Swiss pediatrician, reported in his PhD thesis, written in 
German, the case of a child suspected of carrying a celiac disease, and described it as 
“fibrocystic disease of the pancreas and bronchiectasis” (1). Two years later, Dorothy 
Andersen, from the Pathological Laboratory, Babies Hospital and the Department of 
Pathology, Royal College of Physicians and Surgeons, Columbia University in New York, 
made, based on the review of one thousand autopsies, a clear description of the “fibrocystic 
disease of the pancreas”, pointing out damage of the pancreatic tissue and associating 
meconium ileus to the disease. For the first time, CF was recognized as a separate entity, 
different from celiac disease (2). Prior to this description, the association made by Karl 
Landsteiner (in 1905) between meconium ileus and pancreas fibrosis was erroneously 
believed to result from an enzyme deficiency (3). Two years after Andersen’s description, 
Blackfan and May reported on thirty-five children with atrophy and fibrosis of the pancreas 
due to thickening of secretions and dilatation of ducts and acini (4). The current terminology 
of Cystic Fibrosis was introduced in 1943 by Sydney Farber (5). 
A recessive transmission of a life-threatening familial condition combining steatorrhea and 
bronchopneumonia, probably corresponding to CF, was suspected by Sir Archibald Garrod in 
1912 (6). An autosomal recessive inheritance was suggested in 1945 by Anderson and Hodges 
following the observation of about a hundred families with CF (7). 
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Before the discovery of the gene responsible for the disease in 1989 by the Lap-Chee group, 
the pathogenesis of CF was not understood, even though primary investigations revealed that 
the salt loss occurred via the sweat glands (8,9). This  major advance allowed to establish an 
accurate diagnostic test of CF consisting in measuring an elevated sweat chloride 
concentration following pilocarpine stimulation by iontophoresis, as originally reported by 
Gibson and Cooke in 1959 (10). In the 80’s, more knowledge was brought up with Paul 
Quinton’s work about chloride impermeability in the sweat gland (11). 
The modern history of CF is dominated by the identification of the CF transmembrane 
conductance regulator (CFTR) gene and of the most clinically relevant F508del 
(c.1521_1523delCTT or p.Phe508del) mutation (12-14). Consequently, the basic defect in CF 
has been better understood as a loss of function of the cyclic AMP-dependent CFTR chloride 
channel. In the 90’s, a number of studies to characterize molecular defects of the gene, 
culminating with the development of an open CFTR1 mutation database 
(http://www.genet.sickkids.on.ca/app), have been addressed. The main goal of the database is 
to assemble information on CFTR mutations, more than 2,000 of them having been reported 
up to now. More recently, the CFTR2 database (http://www.cftr2.org/), collecting clinical and 
molecular data from more than 88,000 patients from 41 different countries has been created 
with the aim of studying genotype-phenotype correlations. 
Due to early referral to specialized, multi-disciplinary reference centers for CF (1955 US 
National CF Research Foundation; 1959 Canada foundation of CF; 1965 in Paris the CF 
International Association) (15) and to more comprehensive care, survival has improved over 
time. While in 1938, 70% of CF babies died within the first year of life (2), the median life 
expectancy of patients in the US reached 40.7 years in 2013 (16). Together with a rational 
nutritional care, multi-disciplinary symptomatic management of patients with CF, including 
chest physiotherapy, inhaled bronchodilators, mucolytic and anti-inflammatory agents to 
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improve mucus clearance and to limit chronic infections, and aggressive antibiotic therapy, 
has contributed to improve survival and quality of life. More recently, numerous efforts have 
been made to find a cure for CF by developing strategies addressing the basic defects of the 
disease. As a proof of evidence that the basic defect is drug targetable, ivacaftor (Kalydeco®) 
has been approved as the first drug to treat the underlying cause of the disease. The drug is a 
small molecule acting as a CFTR potentiator, meaning that it increases the gating function of 
CFTR proteins of class III CFTR mutations, such as G551D, normally expressed at the 
plasma membrane of epithelial cells (17); more details on class mutations are given in section 
4. The number of mutations that can be targeted by ivacaftor has expanded (currently 10 
mutations are targeted: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, 
S549R and R117H). Used as a monotherapy, the drug targets about 5% of the CF community. 
In July 2015, Orkambi®, the combination of ivacaftor and lumacaftor, was approved for 
patients displaying at least one F508del allele. Lumacaftor is a small molecule acting as a 
corrector of the misfolded F508del mutated protein, with good preclinical correcting effects in 
vitro and ex vivo (18) but with only modest effects in patients (19, 20). TranslarnaTM 
(ataluren, PTC124) is another small molecule currently in phase III clinical development for 
read-through of CFTR nonsense mutations. The drug is believed to interact with ribosomes to 
enable read-through premature nonsense stop signals on mRNA, thus allowing cells to 
produce a full length protein; the drug is used to target class I mutations, such as G542X (21). 
Ataluren has recently received conditional approval for Duchenne muscular dystrophy, 
another disease associated with premature stop codons. Despite these developments, we still 
lack answers to many questions on the pathogenesis of the disease, and there is still no cure 
for CF. 
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2. Clinical description of CF 
CF is the commonest lethal recessive autosomal disorder in Caucasian populations, with an 
average incidence of 1 in 3,000 live births in European countries (22). It is an exocrine gland 
multisystemic disorder, in which chronic respiratory disease and pancreatic insufficiency 
dominate the clinical picture. Beside sino-pulmonary disease and exocrine pancreatic 
insufficiency, male infertility and high concentrations of sweat electrolytes are among the 
most typical manifestations. The full spectra of phenotypic characteristics in CF are shown on 
Figure 1. CF is one of the most frequent types of chronic lung disease in children and young 
adults, and pulmonary involvement is the major cause of morbidity and mortality. Meconium 
ileus occurs at birth in 15 to 20% of newborns with CF (23). In 85 to 90% of children with 
CF, the pancreatic parenchyma is gradually destroyed, leading to exocrine pancreatic 
insufficiency with protein and fat malabsorption (22). As patients with CF now live longer 
than before, glucose intolerance and cystic fibrosis-related diabetes (CFRD) are becoming 
common complications. Extensive exocrine pancreatic damage is associated with progressive 
loss of endocrine pancreatic tissue, represented by a reduction of the number of Langerhans 
islets, that may contribute to the development of CFRD, the etiology of which is still not 
completely understood (24). More than 95% of males with CF are infertile as a result of 
obstructive azoospermia caused by atrophic, fibrotic or even absent Wolffian duct structures; 
their complete absence is known as CBAVD (for congenital bilateral absence of vas 
deferens). 
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Figure 1. Spectrum of clinical manifestations in Cystic Fibrosis  
 
The phenotypic spectrum spans from mono- to polysymptomatic disease, and from atypical to 
classical CF (25). The severity of involvement within a specific organ, as well as the number 
of affected organs, varies widely from patient to patient, even among those displaying the 
same genotype. The factors related to the large and complex variability are not fully 
understood. Moreover, oligo- or mono-symptomatic patients are usually diagnosed later in 
life, presenting diagnostic, prognostic and therapeutic challenges, in particular considering 
that rare and low prevalent mutations are usually found in such cases. It has been recognized 
that beside genetic factors directly related to CFTR mutations, the presence of residual 
chloride secretion, either by CFTR channels or by alternative chloride channels and of 
environmental factors (e.g., recurrent pulmonary infections, tobacco (26), pollution (27), 
socioeconomic status (28), or compliance to therapy), can influence the CF phenotype. 
Moreover, genetic factors extrinsic to CFTR known as modifier genes have been recently 
studied. Several genes involved in the modulation of the inflammatory response have been 
pointed out. Convincing candidates have been highlighted: the presence of alleles linked to a 
reduced expression of the MBL2 (mannose-binding lectin 2, located at the chromosome 10q), 
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or to an exaggerated expression of TGF-β (transforming growth factor beta, located at 
chromosome 19q) and of EDNRA (endothelin receptor gene A, located at chromosome 4q), 
(29). Additionally, a microsatellite CATT localized in the macrophage migration inhibitory 
factor (MIF) promoter has been reported to be a possible candidate capable of influencing the 
disease severity in patients homozygous for the F508del mutation (30). 
Clinically, typical CF is characterized by the accumulation of viscous mucus in the airways, 
gastrointestinal tract and numerous other organs. In the respiratory tract, this leads to chronic 
obstruction, fibrosis, and ultimately destruction of the lung tissue architecture. The most 
prominent symptoms in the airways are cough, tachypnea and wheezing due to recurrent and 
chronic bronchopulmonary infections. The intestinal malabsorption and pancreatic 
insufficiency lead to steatorrhea and failure to thrive. Exploring sweat gland abnormalities, 
characterized by production of sweat with elevated chloride and sodium concentrations, 
provides the rationale for the development of the sweat test, the gold standard diagnostic 
method. 
 
2.1 Respiratory tract 
At birth, the macroscopic and microscopic appearance of the airways has been described as 
normal, suggesting that airway disease develops postnatally (31). Over the first months of life, 
pathology starts in small airways, bronchioles become plugged with mucus and bronchiolar 
mucosae become inflamed (32,33). However, studies have shown that inflammation is present 
very early in life in CF infants, even in the absence of any detectable infection in response to 
current or previous infection (34-37). 
Progressive accumulation of highly viscous mucus in the airways impairs mucociliary 
clearance and causes bronchiolitis and bronchitis, and eventually bronchiolectasis and 
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bronchiectasis. At end-stages, disseminated bronchiectasis is recognized as irreversible 
dilatation of thick-walled bronchi with airflow obstruction, inflammation and collapse. The 
airway submucosal glands and goblet cells, both involved in mucus production, also seem 
normal at birth, but progressively become obstructed with mucus resulting in dilatations and 
hypertrophy. Mucus hyperproduction and plugging that typifies CF is also a consequence of 
mucous cell metaplasia and up-regulation of mucin gene expression by inflammation. Altered 
airway cilia structure and function, also found in patients with CF, may contribute to 
impairing mucociliary clearance (38,39). At the end-stage of the lung disease, final disruption 
of lung architecture leads to sustained decline in lung function to such an extent that lung 
transplantation becomes the only option for improving quality of life and survival.  
 
Most CF patients have chronic rhinitis with inflammation and irritation of the nasopharyngeal 
mucosa that can contribute to the development of nasal polyps. As a matter of fact, beginning 
in preschool age, during their lives, up to 50% of patients with CF experience obstructing 
nasal polyposis. Enlargement of terminal phalanges of fingers and toes, known as digital 
clubbing, is fairly common in patients with CF and is generally considered indicative of 
extensive pulmonary disease.  
The progression of lung disease is associated with repeated chronic lung infections by 
opportunistic pathogens. Typically, Staphylococcus aureus and Haemophilus influenza are the 
first detected microbial agents (40), and infection with Pseudomonas aeruginosa, a 
predominant biofilm-forming pyogenic bacterial pathogen in CF, overcomes at later stages. 
Colonization with P. aeruginosa is associated with an faster decline of pulmonary function. In 
end-stage CF lung disease, P. aeruginosa can co-exist with other microorganisms competing 
for the same pool of resources. Additionally, Burkholderia cepacia complex organisms are 
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important respiratory pathogens in patients with CF. Infection with B. cepacia complex 
organisms can result in increased mortality and morbidity (41). 
Although the exact mechanism of lung infection is not yet fully understood, it seems clear that 
accumulation of thick mucus with impaired mucociliary clearance creates a favourable 
environment for development of pathogens. 
 
2.2 Gastrointestinal tract 
Pathological changes of the mucosa of the gastrointestinal tract are minimal and consist in 
dilatation of ducts and acinar lumens of the Brunner glands in the duodenum due to mucus 
accumulation. As in airways, goblet cell hyperplasia is a common finding, especially in the 
appendix, together with increased amounts of mucous material within crypts and lumen of the 
gastrointestinal tract. 
Thick meconium plugs in the lumen of the gastrointestinal tract is the first clinical 
manifestation in CF observed in prenatal stages as early as 17 weeks of gestation (42-44), 
both from autopsy material and from in utero echography examinations. These 
gastrointestinal abnormalities can occur irrespective of changes in any other organ (45). The 
accumulation of meconium plugs can develop into total obstruction of the distal ileum, failure 
to pass meconium, abdominal distension and emesis. A meconium plug syndrome occurs in 
10 to 15% of newborns with CF, usually presenting within 48 h after birth, or even earlier 
when complications such as volvulus, intestinal wall perforation or meconium peritonitis arise 
(46,47). Babies with meconium ileus should always be evaluated for CF, as very few other 
conditions can cause it and up to 90% of infants with the clinical picture have CF (48). 
The pathogenesis of meconium ileus has been attributed to pancreatic insufficiency and to 
consequent indigestion of the intestinal intraluminal contents (49). Abnormal transmucosal 
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transport and dehydration of extramucosal liquid layers leading to increased viscosity of the 
intestinal mucus contribute to the underlying pathophysiological mechanism (50,51). 
Meconium ileus is clearly associated with homozygosity for the F508del mutation, commonly 
causing pancreatic insufficiency, whereas mutations that do not impair pancreatic function are 
only rarely found in association with meconium ileus (52). Moreover, non-CFTR genes, 
known as modifier genes, also influence the risk of developing meconium ileus. Genome-
wide analyses have suggested ADIPOR2 and SLC4A4 as candidate modifier genes, although 
the mechanisms underlying the relationship with meconium ileus are still unknown (53). 
After the neonatal period, distal intestinal obstruction syndrome (DIOS, formerly designated 
“meconium ileus equivalent”), and constipation with complete or incomplete intestinal 
obstruction of viscid fecal accumulation in the terminal ileum and proximal colon occur in 
about 20% of patients with CF. 
Bicarbonate secretion in the duodenum, a protective mechanism neutralizing gastric acidic 
secretions, has been shown to be defective in CF. Indeed, it has been shown that functional 
CFTR is required for cAMP-stimulated electroneutral bicarbonate secretion involving the Cl-
/HCO3- exchanger (54). This impairment might contribute to the gastrointestinal complaints 
of patients with CF. 
 
2.3 Pancreas 
Exocrine pancreatic insufficiency is present in the vast majority (up to 95 %) of patients with 
CF (55), with pathological pancreatic changes, consisting of dilated ducts and acini owing to 
thick and inspissated pancreatic secretions, already detectable during intrauterine life (56). 
Detection of high levels of immunoreactive trypsin-like activity (IRT) by newborn screening 
programs demonstrates the capacity of the neonatal parenchyma pancreas to secrete enzymes, 
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but excretion is impaired due to ductal obstruction (57). The major role of CFTR in pancreatic 
ducts is to dilute and to alkalinize the protein-rich acinar secretions. Progressive loss of acinar 
cells and areas of destruction are replaced by fibrous tissue and fat. Later in the progression of 
the disease, islets of Langerhans, the functional units of the endocrine pancreas, become 
affected with deformation by fibrous tissue and destruction of insulin producing β-cells. 
These abnormalities contribute to the development of glucose intolerance and CFRD. 
The severity of the pancreatic enzyme and bicarbonate deficiency is variable. It increases with 
age (58-60) and seems to be genetically determined (61). Fat loss in stools (steatorrhea), due 
to insufficient secretion of lipolytic enzymes to digest and absorb fat associated with 
deficiency in fat-soluble vitamins, correlates with massive (more than 90%) destruction of 
pancreatic exocrine tissue. Patients displaying steatorrhea are classified as pancreatic 
insufficient (PI), while those (10-15%) showing less severe pancreatic changes with some 
remaining functional pancreatic tissue are classified as pancreatic sufficient (PS). The PI 
status is associated with more severe mutations like F508del while the PS status seems to 
better correlate with milder CFTR mutations. Pancreatic insufficiency is defined by faecal fat 
loss above 7 g/day, fat absorption below 93% during a 3-day faecal fat balance or faecal 
elastase below 200 μg/g. While fat loss is increased in stools, faecal elastase-1 activities are 
increased in PI patients. (62). Symptomatic treatment of the pancreatic insufficiency status 
includes pancreatic enzyme supplements (63) and structured follow up of nutritional status. 
 
2.4 Hepatobiliary tract 
CFTR is normally expressed in bile ducts. It has long been recognized in post-mortem 
analyses that liver abnormalities, found in up to 50% of autopsies of patients with CF, 
integrate the spectra of phenotypic characteristics of the disease (64,65). Liver morphological 
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changes include inspissated secretions, biliary duct proliferation, periportal inflammation and 
fibrosis. Fibrotic areas surround patches of normal liver parenchyma with a lobular aspect. 
Additionally, gallbladder abnormalities include hypoplasia of the gallbladder, stones 
containing calcium and protein, and thick, white, mucous contents (66). 
Symptomatic liver disease is found in approximately 5-10% of patients. Multilobular cirrhosis 
occurs early in the first decades of life, with signs of portal hypertension and liver failure 
developing later in childhood (67). Clinical manifestations may include hyperbilirubinemia, 
ascites, peripheral edema, or hematemesis due to eosophageal varices (68). In contrast to the 
pancreatic involvement in CF disease, there is no clear genotype-phenotype association in CF 
liver disease (69). 
 
2.5 Genital tract 
Male patients with CF develop normal secondary sexual characteristics and sexual 
maturation, yet almost all (~ 97%) of them are infertile due to obstructive azoospermia 
attributed to congenital absence of the vas deferens (CBAVD). Genital male abnormalities 
encountered in CF include bilateral atrophic or absent vas deferens and body and tail of the 
epididymis, and seminal vesicles are dilated, fibrotic, or also absent (70). As a consequence, 
no spermatozoa are present in the ejaculate due to obstruction of the vas deferens, whereas 
testicular biopsies show that spermatogenesis is preserved. With increasing survival of 
patients with CF, a need of micro-assisted reproduction techniques, such as testicular sperm 
extraction and intracytoplasmic sperm injection, have emerged as beneficial methods to 
enable these patients to father children of their own (71). 
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Reduced female fertility might exist through reduced water content of the cervical mucus, 
which hinders sperm passage (72). Other disturbing factors are chronic pulmonary sepsis 
initiating menstrual irregularities, and possible cysts in the ovaries (73). 
 
2.6 Sweat glands 
During the summer of 1949 in New York City, an unusually intense heat wave struck, 
bringing to Dr Paul di Sant ‘Agnese, a clinician, the suspicion that the accentuated 
dehydration presented by children with CF was due to pure salt loss. Gibson and Cooke 
meticulously demonstrated that sweat glands were the site of the ion loss in these children 
(G&C). This was the basis of the introduction of the “Quantitative Pilocarpine Iontophoresis 
Sweat Test” (QPIT) still used nowadays as the gold standard diagnostic test in CF. 
In practice, sweat gland secretion is stimulated by iontophoresis of pilocarpine, a cholinergic 
agent, and sweat is collected for 30 minutes using either filter paper or the Macroduct sweat 
collection system (Wescor Inc, Logan, Utah) (Figure 2). Sweat chloride concentration is 
measured by quantitative analysis techniques such as colorimetry, coulometry, etc. Currently, 
according to the European Coordination Action for Research in Cystic Fibrosis (EurocareCF) 
(http://www.eurocarecf.eu) and the European Cystic Fibrosis Society (ECFS) Diagnostic 
Network Working Group (http://www.ecfsoc.org), established cutoff sweat chloride 
concentrations are: normal: <30 mmol/L; intermediate: 30-60 mmol/L; and abnormal :> 60 
mmol/L. However, it has been well established that a fraction of patients with a diagnosis of 
CF have a sweat chloride value < 60 mmol/L. As a matter of fact, some mutations, i.e. 
A455E, 3849+10kbC>T, R117H, L206W, … are described with borderline (30-60 mmmol/L) 
or normal (<30mmmol/L) chloride concentrations (74,75). 
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Figure 2. Collection methods of sweat test. A iontophoresis electrodes on the forearm. B 
Wescor collection method. C Filter paper collection. 
  A    B     C
 
 
3. CFTR-related disorders 
A CFTR-related disorder has been described as « a clinical entity associated with CFTR 
dysfunction that does not fulfil diagnostic criteria for CF » (24,76). The picture is comprised 
of three main clinical entities, all associated with CFTR dysfunction: CBAVD (congenital 
bilateral absence of the vas deferens), acute recurrent or chronic pancreatitis and disseminated 
bronchiectasis (24). Additionally, ABPA has been considered as a CF-related disorder (77). 
More recently, CFSPID (CF screening positive inconclusive diagnosis) has been suggested as 
a CF-related disorder. The terminology has been adopted to describe the sometimes 
challenging case of a child with a positive newborn screening test, later changed into an 
inconclusive diagnosis of CF (78). In clinical practice, it is advisable that the child graduates 
to a proper CF care unit, assuming the possibility, even limited, of conversion to CF. The 
follow-up should include repeating the sweat test  (at 6 and 12 months of age, then annually) 
and the fecal elastase test later. To assist in the diagnosis, other diagnostic tests such as the 
nasal potential difference test and intestinal current measurements in tissues obtained from 
rectal biopsies are helpful. In the USA, the CFSPID has been termed "CFTR-related 
metabolic syndrome" (CRMS) (79). 
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3.1 CBAVD 
CBAVD is the clearest example of a CFTR-related disorder. As such, isolated CBAVD 
occurs in men with mild pulmonary or gastrointestinal manifestations of CF or even without 
any detectable CFTR dysfunction. The expression "CFTR-related disorder" for isolated 
CBAVD associated with at least one CFTR-causing mutation has been considered more 
appropriate than other common terminologies such as mild, atypical or non-classic CF. The 
absence of vas deferens is part of the clinical picture of classical CF. In all cases of CBAVD, 
affected men have azoospermia (absence of sperm in the semen) and are infertile. Isolated 
CBAVD accounts for approximately 3% of cases of male infertility (incidence around 1:1000 
males). In contrast with classical forms of CF, the prevalence of isolated CBAVD does not 
appear to be linked to ethnic factors and does not vary among populations.  
In subjects with CBAVD, the most common CF-causing mutation is p.Phe508del varying 
from 21-33% (in Canada, USA, Northern Europe) to 12-18% (in India and Southern Europe). 
These frequencies are much higher than those found (4%) in control European populations. 
The frequency of the 5T allele in the general population is 5%, but it is higher in the CBAVD 
populations (Indians 25%, Japanese 30%, Egyptians 44%, Taiwanese 44%). In about 70-90% 
of cases with CBAVD, a compound heterozygous status is identified with combination, in 
trans position, of a « severe » (class I to III) and a « mild » CFTR mutation (class IV to V). 
The two most common compound heterozygous genotypes found in European subjects with 
CBAVD are p.Phe508del with a 5T allele (28%) and p.Phe508del with p.Arg117His (6%). 
The 5T allele is considered as a CBAVD mutation with incomplete penetrance. It has been 
well established that the combination of the T(5-9) repeats with that of TG dinucleotide, 
usually varying from 10-13 repeats and lying immediately upstream of the former, influences 
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the efficiency of exon 9 splicing (80). Longer TGm repeats in cis with shorter Tn repeats are 
associated with increased exon 9 skipping, and lead to production of misfolded and 
nonfunctional CFTR protein and correlate with a more severe CBAVD or CFTR-related 
phenotype. (81,82). 
The diagnosis of CFTR-related CBAVD is established in males with azoospermia with low 
volume (<2 mL; normal: 3-5 mL) of ejaculated semen and absence of vas deferens, possibly 
associated with abnormalities of seminal vesicles. Rarely, a thin fibrous cord representing a 
rudimentary vas deferens may be present. Additionally, a specific chemical profile including 
acidic sperm (average pH <6.8; normal pH >8), elevated citric acid concentration (>2000 
mg/100 mL; normal: 400-1500 mg/100 mL), elevated acid phosphatase concentration (760-
1140 mµ/mL; normal: 140-290 mµ/mL) and low fructose concentration (30-80 mg/100 mL; 
normal: 250-720 mg/100 mL) can be found. 
 
3.2 Idiopathic Chronic Pancreatitis 
Chronic pancreatitis is defined as a long-standing inflammatory destruction of the pancreatic 
parenchyma, finally leading to tissue fibrosis. The disease is characterized by variable 
abdominal pain, calcifications, necrosis, fatty replacement, fibrosis and scarring, and other 
complications. Chronic pancreatitis rarely causes diabetes. Diabetes due to chronic 
pancreatitis is characterized by a low incidence of ketosis and a high incidence of insulin-
induced hypoglycaemia. Obstructive pancreatitis is due to an obstacle (tumours, scars) in the 
pancreatic duct. Calcifications, also signing the chronic inflammation, are like stones 
embedded in the tissue itself or in the pancreatic duct. 
The estimated incidence of chronic pancreatitis in adults is 3.5-10 cases per 100,000. In 
developed countries, 60–70% of patients with chronic pancreatitis have a history of excessive 
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alcohol intake, while in 30% of cases, the disease is considered idiopathic. Variability in 
susceptibility to idiopathic chronic pancreatitis seems to be related to genetic differences 
among patients. Plugging of the smaller pancreatic ducts is a frequent early finding in 
idiopathic chronic pancreatitis (ICP) in which progressive obstruction finally leads to 
pancreatic injury. 
CFTR protein is expressed at the external membranes of epithelial cells lining the normal 
ducts of the human exocrine pancreas, where it regulates bicarbonate secretion through a 
cAMP-dependent pathway. The major role of CFTR in pancreatic ducts is to dilute and to 
neutralize acinar solutions that are rich in protein. Through this mechanism, CFTR protects 
the tissue against formation of protein aggregates and tissue damage. The fact that a loss-of-
function of CFTR protein of > 98% is needed to produce pancreatic insufficiency (i.e. 
homozygous p.Phe508del) illustrates the large functional reserve of the pancreas.  
About 30% of patients with ICP display CFTR mutations. About two-thirds of them carry 
common CFTR mutations and a small fraction (~ 6%) is compound heterozygous combining a 
CF-causing mutation and a milder CFTR allele. Although there is no clear genotype-
phenotype relationship regarding the development of ICP, rare class IV or class V mutations 
are generally associated with pancreatitis (24). The pancreatitis risk increases 40-fold in the 
presence of two CFTR mutations (83). 
An association between some genetic non-CFTR mutations and chronic pancreatitis (CP) has 
been recognized for a long time. ICP can also result from mutations in the cationic 
trypsinogen gene (PRSS1), and the serine protease inhibitor Kazal 1 (SPINK1) genes. In 1996, 
the first mutation associated with hereditary pancreatitis, namely the R122H mutation in the 
PRSS1, was identified (84). Several other mutations (A16V, K23R, N29I, N29T, R122C) and 
triplication as well as duplication of the PRSS1 locus have been subsequently described (85). 
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The effect of mutations in the SPINK1 gene, considered as a susceptibility gene, on the onset 
of pancreatitis was reported in 2000 (86,87). The most frequent SPINK1 mutation is N34S. 
The pancreatitis risk increases 20-fold in the presence of N34S mutation in the SPINK1 gene 
and 900-fold in the presence of both CFTR and SPINK1 mutations (83). 
 
3.3 Allergic Bronchopulmonary Aspergillosis 
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary hypersensitivity mediated 
by an allergic response to Aspergillus fumigatus.  There are approximately 250 different 
species of Arpergillus, but only a few of them are known human pathogens. Depending on the 
host/pathogen equation, the respiratory diseases caused by Aspergillus are classified as 
allergic (allergic Aspergillus sinusitis, hypersensitivity pneumonia and ABPA), saprophytic 
(aspergilloma) and invasive (airway invasive aspergillosis, chronic necrotizing aspergillosis, 
and invasive aspergillosis).  
Multiple immunological features combining immediate type 1 hypersensitivity, antigen-
antibody type III reactions, and eosinophil-rich inflammatory type IVb responses have been 
described in ABPA (88). However, a predominant T-helper 2 lymphocyte response to 
Aspergillus fumigatus infection without tissue invasion seems to be well characterised, 
leading to mucus production, airway hyperactivity and, finally, bronchiectasis.  
Clinically, ABPA manifests itself as chronic poorly controlled asthma, recurrent pulmonary 
infiltrates and bronchiectasis.  In asthma or CF, most patients with ABPA present with 
wheezing, bronchial hyperreactivity, hemoptysis, productive cough, low-grade fever, malaise, 
weight loss, and/or worsening symptoms; however asymptomatic forms are recognised. The 
diagnosis of ABPA is currently based on the most recent criteria reported in 2012 in the 
Journal of Allergy and Clinical Immunology (89). According to the paper, the minimal 
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criteria to establish the diagnosis include deterioration of lung function in patients with 
asthma or CF, positive test for immediate skin reactivity to Aspergillus species (prick skin 
test), elevated total serum IgE (> 1000ng/mL), increased Aspergillus species-specific IgE and 
IgG antibodies and the presence of chest radiographic infiltrates (90,91). Despite these criteria 
(89), the diagnosis of ABPA in patients with CF remains challenging. It is believed that 
ABPA most probably remains underdiagnosed.  
In the general population, the prevalence of ABPA is unknown but it is believed to be as high 
as 2.5% (92). Although ABPA is most commonly diagnosed in adults, its prevalence in 
children is increasing and the condition is very unusually found in children outside the context 
of CF.  In patients with CF, the prevalence of ABPA has been reported as varying from 2 to 
15% (93). Its increased frequency in patients with asthma or CF is consistent with a genetic 
susceptibility to ABPA. 
Patients with disseminated bronchiectasis carry at least 1 CFTR mutation in 10-50% of the 
cases, and 5-20% carry 2 mutations. In a letter published in Thorax (94) extending an earlier 
DNA analysis, it has been shown that the CFTR mutation carrier frequency can be as high as 
67% (12/18), which is close to the estimate for CBAVD. 
 
4. The CFTR gene 
The large spectrum of phenotypes (detailed in paragraph 3) associated with variable degrees 
of severity of typical and atypical CF disease is caused by mutations in the CFTR gene 
(NG_016465.4). The gene is large, spanning approximately 230kb on the chromosome 7q31.2 
and contains 27 exons, numbered as illustrated in Figure 3.  
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Figure 3. Structure of the CFTR gene.  
A) 
 
 
B) 
 
C) 
 
A) Exons numbering. Rescaled exon scheme (introns are not drawn to scale). Numbers above 
(1 to 24) correspond to the old nomenclature (legacy name). Numbers below (1 to 27) 
correspond to the new nomenclature (HGVS). 
B) Corresponding numbering and reading frame for exons and nucleotides. Inside each box, 
white numbers refer to exons labelling corresponding to the old nomenclature (legacy name) and red 
numbers to the new nomenclature (HGVS). Numbers in black correspond to codon numbers. Red 
numbers under boxes correspond to nucleotide numbers in the CDS (NM_000492.3). 
C) Meaning of boxes' edges: round-shaped edges indicate exon ending at the first nucleotide; arrow-
shaped edges indicate exon ending at the second nucleotide; flat edges indicate exons ending at the 
third nucleotide. 
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5. The CFTR protein 
The encoded mRNA (NM_000492.3) is about 6.5 kb in length and is translated into a protein 
product of 1480 amino acids (NP_000483.3). A putative structure of the CFTR protein has 
been drawn on the basis of the amino acid sequence. It is a member of the superfamily of 
ATP-binding cassette (ABC) transporters, in particular it is categorised as a sub-family C 
member 7 (ABCC7). The predicted protein structure is composed of two repeated units, each 
consisting in a membrane spanning domain (MSD) comprised of six hydrophobic 
transmembrane helices, followed by a nucleotide-binding domain (NBD) that interacts with 
ATP. Ten of the 12 transmembrane helices contain one or more charged amino acids, and two 
potential glycosylation sites are found between helices 7 and 8. The 6-helical domains of 
MSD1 span from residues 82 to 103, 119 to 139, 196 to 216, 222 to 243, 309 to 329 and 330 
to 351 interlinked by three short extracellular loops and two longer intracellular loops (Figure 
4). The 6-helical domains of MSD2, also interlinked by two intracellular and three 
extracellular loops, span from residues 880 to 900, 944 to 964, 1023 to 1043, 1046 to 1066, 
1135 to 1155, and 1161 to 1182. NBD1 and NBD2 correspond to the amino acid sequences 
433-584 and 1219-1382 respectively (Figure 4). The two repeated units are linked by a single 
regulatory (R) domain that spans from amino acid residues 590 to 831 and contains 9 of the 
10 consensus sites for phosphorylation by protein kinase A (PKA) and 7 of the 
phosphorylation sites for protein kinase C (PKC). The R domain is unique to CFTR as it is 
not present in any other member of the ABC superfamily. The transmembrane helices 
assemble to line the pore of the anion-selective channel (95) through which chloride ions can 
flow across the plasma membrane (96). Anion flow through the channel is believed to be 
gated by cAMP-dependent PKA phosphorylation of the R domain (97,98) and by binding of 
ATP to NBD sites that induces conformational changes in the protein, finally controlling its 
open probability 
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(96,99-102). 
Figure 4. Protein CFTR structure 
 
Numbers correspond to amino acid positions in the polypeptide chain. 
 
6. Mutations in the CFTR gene 
Under physiological conditions, the CFTR gene undergoes transcription and is translated into 
a CFTR protein that trafficks to the cell membrane where it mainly functions as a chloride 
channel (Figure 4). In CF, the majority of CFTR mutations involve changes in three or fewer 
nucleotides and result in amino acid substitutions, frame shifts, splice site, or nonsense 
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mutations. The most common and also the first identified mutation, p.Phe508del, corresponds 
to a three base pair deletion that codes for a phenylalanine at position 508 of the protein. 
However, the relative frequency of the p.Phe508del mutation in families carrying the CF gene 
varies among ethnic groups. An increasing South East–North West gradient has been noticed 
for its relative frequency across European countries: the highest frequency of 82% is reached 
in Denmark but the mutation is much less frequent in Mediterranean regions, where less than 
50% of chromosomes with the CFTR gene have the mutation (103). The overall frequency of 
non-p.Phe508del mutations is low, except for some rare alleles that segregate with a specific 
ethnic group. For instance, the W1282X, a stop codon mutation, accounts for 48% of CF 
chromosomes in Ashkenazi Jews (104), and 23% of French Canadian CF chromosomes carry 
the 621+1G>T variant (105,106). It is the presence of the p.Phe508del mutation that increases 
the frequency of CF in Caucasian population relative to other races. 
CFTR mutations have been described in six different classes (Table 1). Class I mutations 
result in an absence of functional CFTR protein (caused by unstable truncated RNA); they 
correspond to nonsense, frameshift canonical splice. This class contains for example 
p.Gly542*, p.Trp1282*, p.Arg553*, c.489+1G>T mutations. Class II result in CFTR 
trafficking defects (full length CFTR RNA but protease destruction of misfolder CFTR); they 
correspond to missense or amino acid deletion. Examples of class II mutations include 
p.Phe508del, p.Asn1303Lys, p.Ile507del, p.Arg560Thr mutation. Class III produce a CFTR 
protein at the cytoplasmic membrane but with defective channel regulation; they correspond 
to missense or amino acid change. This class contains for example the p.Gly551Asp, 
p.Gly178Arg, p.Gly551Ser, p.Ser549Asn mutations. Class IV produce a CFTR protein at the 
cytoplasmic membrane but with a defective CFTR channel with decreased channel 
conductance; they correspond to missense or amino acid change. This class contains for 
example the p.Arg117His, p.Arg347Pro, p.Arg117Cys, p.Arg334Trp mutations. Class V 
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induce a reduced synthesis of CFTR caused by splice defect or missense. This class contains 
for example the 3849+10kbC>T, 2789+5G>A, 3120+1G>A and 5T mutations. Class VI lead 
to decreased CFTR membrane stability; they correspond to missense or amino acid change. 
This class contains for example the c.4196_4197delTC, p.Gln1412* and c.4147_4148insA 
mutations. 
Table 1. Classes of CF mutations 
Class Resulting CFTR 
defect  
Mutation Type Examples 
I No protein Premature stop codon, 
larges deletions, out-of-
frame deletion, insertion 
p.Gly542* 
p.Trp1282* 
p.Arg553* 
c.489+1G>T 
II Processing defect Missense, amino acid 
deletion 
p.Phe508del 
p.Asn1303Lys 
p.Ile507del 
p.Arg560Thr 
III Regulation defect Missense p.Gly551Asp 
p.Gly178Arg 
p.Gly551Ser 
p.Ser549Asn 
IV Decreased 
conductance 
Missense p.Arg117His 
p.Arg347Pro 
p.Arg117Cys 
p.Arg334Trp 
V Reduce synthesis Missense, change in splicing 
efficiency 
3849+10kbC>T 
2789+5G>A 
3120+1G>A 
5T 
VI Altered channel 
stability 
Nonsense, frameshift c.4196_4197delTC 
p.Gln1412* 
c.4147_4148insA 
 
 
7. Molecular diagnosis of CFTR 
The consensus strategy for molecular diagnosis is divided in two groups. The first line 
strategy aims at detecting known mutations using commercial kits. The second line aims at 
detecting unknown mutations, using a gold standard DNA sequencing method.  
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In Europe, due to heterogeneity of distribution of mutations, a local detection rate higher than 
95% is difficult to achieve (with mutation frequencies of more than 1%). Panels of mutations 
commonly used recognise from 20 to 86 CF-causing mutations.  
In the USA, the situation is unambiguous. The American College of Medical Genetics 
(ACMG)/American College of Obstetricians and Gynecologists (ACOG) have recommended 
a core panel of 23 mutations to be included in the first line strategy. 
When a CF phenotype is suspected and no or only one known mutation in the panel has been 
detected, a search is made for a rare CF-causing mutation. This second line sequences the 
coding exons (CDS) and bordering intronic regions for punctual mutations (SNV), and the 
Multiplex Ligation-dependent Probe Amplification (MLPA) for large rearrangements (CNV). 
Nowadays, the complete intronic nucleotide sequencing is not routinely applied in molecular 
diagnostic laboratories. 
 
8. CFTR1 database 
In 1990 the international Cystic Fibrosis Genetic Analysis Consortium (CFGAC) created the 
‘cftr1’ mutation database (http://www.genet.sickkids.on.ca/PicturePage.html) in the CF 
Centre at the Hospital for Sick Children in Toronto. On August 25 2016, 2009 variants had 
been introduced in the database. Their distribution into categories is given on Table 2. 
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Table 2. Distribution of variants in the CFTR gene  
Mutation Type Count Frequency % 
Missense 795 39.57 
Frameshift 313 15.58 
Splicing 228 11.35 
Nonsense 167 8.31 
In frame in/del 41 2.04 
Large in/del 52 2.59 
Promoter 15 0.75 
Sequence variation 269 13.39 
Unknown 129 6.42 
The usefulness of the database is limited by its composition: a list of individual patients with a CF- or 
a CF-related phenotype and carrying a new suspected pathological variant in the CFTR gene. 
 
9. CFTR2 database 
More recently, a second CF mutation database “CFTR2” for “Clinical and Functional 
Translation of CFTR” (http://www.cftr2.org/) was created, in an attempt to correlate 
phenotype with genotype (including the allelic distribution in cis or in trans) in groups of 
patients carrying the same mutation. It was based on the collection of clinical data of almost 
88,000 patients from 25 European and North-American datasets, namely CF registries and CF 
centers. Despite the very large size of the set of patients, only 273 mutations have been 
included (http://cftr2.org/progress.php). Clinical data taken into consideration are sweat 
chloride, lung function, pancreatic status and presence of Pseudomonas. The database 
classifies mutations into four categories labelled « disease-causing », « neutral », « mutation 
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of varying clinical consequences » and "mutations of unknown clinical significance", and 
provides clinical information about complex alleles containing more than one variant (107). 
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Objectives 
The general aim of this work is to analyse the spectrum of CFTR mutations in CF and in CF-
related disorders.  The severity of classic forms of the disease and the number of affected 
organs varies substantially from patient to patient, even among those displaying the same 
genotype. The presence of CFTR mutations can also be associated with CF-related disorders, 
such as ABPA and pancreatitis. The factors related to the large and complex variability in CF 
are not well recognized and a large spectrum (more than 2,000) of CFTR mutations has been 
reported.  
This project specifically aims at investigating the following points: 
1) Validation of a new diagnostic screening method (xTAG Luminex) for routine 
analysis compared to the INNO-LiPA® method (Innogenetics) used as a reference. 
2) Characterisation of frequencies of CFTR mutations in central Argentina with the 
final aim of developing a new first line panel of mutations with high sensitivity for 
routine use in this population. 
3) Study of the clinical manifestations, including the occurrence of pancreas cancer, 
in patients with sporadic idiopathic pancreatitis who display mutations in the 
CFTR, PRSS1 and SPINK1 genes. 
4) Better characterisation of the nature of CFTR mutations, by sequence analyses, in 
a group of adult patients with ABPA. 
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Personal Research 
New Molecular Screening Assay for Increased Detection Rate 
of CFTR Mutations in European Populations 
Xavier Pepermans1, Marianne Philippe1,2, and Teresinha Leal1,2,3 
1. Centre for Human Genetics, Cliniques Universitaires Saint-Luc; 2. Department of Clinical 
Biology, Cliniques Universitaires Saint-Luc; 3. Louvain Centre for Toxicology and Applied 
Pharmacology, Université Catholique de Louvain 
European Respiratory Review, 2010; 6: 62–65 
In 2009, all Belgian Genetics centers used the same panel of 36 mutations (the gold standard 
at the national level) for the first line molecular diagnosis of the CFTR gene. At that time, a 
US-based company contacted me with an alternative single panel of the 71 most frequent 
mutations for Europe as the whole. The rationale was that “it was better suited for patients of 
southern European descent”, who are characterised by a large diversity of mutations.  
This work has been designed to address the first objective of the thesis project, namely, to 
investigate the validation of a new diagnostic screening method (xTAG Luminex) for routine 
analysis compared to the INNO-LiPA® method (Innogenetics) used as a reference. The paper 
below compares the two panels and presents mutation detection rates for countries from 
northern, central and southern Europe separately, with data from the national registries. This 
paper tried to answer the question : “what is the advantage of using a panel with twice the 
number of mutations in the first line molecular diagnosis?”. Since then, the UCL and ULg 
Genetics centers use the new panel in first line routine diagnosis.  
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Identification and frequencies of cystic fibrosis mutations in 
central Argentina 
Xavier Pepermansa,b, Soledad Melladoc, Sergio Chialinac,d, MartaWagenere, Liliana Gallardof, 
Hilda Landef, Walter Bordinod, Daniel Barang, Vincent Boursa, Teresinha Lealh 
aCenter for Human Genetics, CHU Sart-Tilman, Université de Liège, Liège, Belgium; bCenter 
for Human Genetics, Cliniques Universitaires St-Luc, Université Catholique de Louvain, 
Brussels, Belgium; cLaboratorio STEM, Rosario City, Santa Fe province, Argentina; dInstituto 
Universitario Italiano de Rosario, Rosario City, Santa Fe province, Argentina; eHospital de 
Niños “Dr. Orlando Alassia”, Santa Fe City, Santa Fe province, Argentina; f Hospital de 
Niños “Víctor J. Vilela”, Rosario City, Santa Fe province, Argentina; gInstitut de la 
Mucoviscidose, Université libre de Bruxelles, Brussels, Belgium ; hLouvain Center for 
Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, 
Université catholique de Louvain, Brussels, Belgium 
Clinical Biochemistry 49 (2016) 154–160 
In 2009 in South-America, a small number of publications identified the mutations of the 
CFTR gene present in the continent. Especially in Argentina, only two papers reported the 
distributions and frequencies of CFTR mutations, one for the Cordoba province and the other 
for Buenos Aires, the capital city. In contrast, all European countries and regions have been 
studied to determine the natures and frequencies of CFTR mutations (and large differences 
have been observed between regions). Argentina was largely populated by a European 
immigration at the end of the 19th century. The rationale of the paper was: “Can CFTR 
mutations of putative precolombian origin be found in a country mainly populated by Italians, 
Spanish, Irishmen, Germans, French, … Europeans?” And a second question arose: "Are 
frequencies similar to those found in Europe?"  
To answer the questions and to address the second objective of my thesis project, namely to 
characterize the frequencies of CFTR mutations in central Argentina with the final aim of 
developing a new first line panel of mutations with high sensitivity for routine use in this 
population, I used my personal contacts in the country. A questionnaire was designed on 
purpose by Prof. Daniel Baran to select a cohort of more than 100 children with classical CF 
in the Santa Fe province of Argentina, and I performed a complete molecular CFTR screening 
of the cohort according to the best European practices. The results are described in the 
following paper.  
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Clinical and morphological characteristics of sporadic 
genetically determined pancreatitis as compared to idiopathic 
pancreatitis: higher risk of pancreatic cancer in CFTR variants. 
a Coralie HamoirФ, b Xavier PepermansФ, a Hubert Piessevaux, c Anne Jouret-Mourin, c Birgit 
Weynand, a Jean-Baptiste Habyalimana, b Teresinha Leal, a André Geubel, d Jean-François 
Gigot, a Pierre H. Deprez* 
aGastroenterology Department, Cliniques universitaires Saint-Luc, Université Catholique de 
Louvain, Brussels, Belgium ; bCenter for Human Genetics. Cliniques universitaires Saint-Luc, 
Université Catholique de Louvain, Brussels, Belgium ; cPathology Department, Cliniques 
universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium ; dDepartment 
of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Université 
Catholique de Louvain, Brussels, Belgium  
Ф
 C.H. and X.P. contributed equally to this study. 
Digestion. 2013; 87(4):229-39. 
The starting point of this paper was a question asked by the UCL Gastroenterology 
Department: “Is it possible to predict, from clinical data, a genetic factor in patients with 
idiopathic pancreatitis (excluding an alcoholic origin)?”. And a second question was: “Are 
patients with pancreatitis and carrying at least one CFTR, PRSS1 or SPINK1 mutation more 
frequently affected than non-carriers?”. 
To answer the questions and to address the third objective of the thesis project, i.e., to study 
the clinical manifestations, including the occurrence of pancreas cancer, in patients with 
sporadic idiopathic pancreatitis who display mutations in the CFTR, PRSS1 and SPINK1 
genes, I thus collected, from the files of the Department of Genetics, the retrospective 
molecular data since 1999 (obtained by me since 2001) of patients from departments of 
Gastroenterology of the whole of Belgium. This constituted a database of 351 patients with 
idiopathic pancreatitis and genetic testing. Out of this cohort, a group of 68 patients carried at 
least one mutation in the CFTR, PRSS1 or SPINK1 genes. From the database of 351 patients, 
the UCL Gastroenterology Department then constituted a non-carrier control group matched 
for gender and age, and compared the clinical characteristics between the two groups. The 
results of the comparison are given in the following paper.  
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Link between CFTR mutations and pancreatic cancer 
Chronic inflammation has long been recognised as an important underlying condition for 
tumor development, accounting for approximately 20 % of human cancers (1). Despite years 
of extensive research, the mechanisms linking chronic inflammation to cancer development 
still look very complex and remain largely unresolved. 
 
1. TNFα and NFκB, major actors in inflammation 
The NFκB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) family of 
transcription factors plays an essential role in inflammation and innate immunity. They are 
strongly expressed in inflammation in response to stimulation by TNFα (Tumor Necrosis 
Factor α), in particular in CF (2). NFκB is considered responsible for increased expression of 
pro-inflammatory cytokines (such as IL-8, chemoattractants for neutrophils,...) (3). It has 
essential roles in the complex flux of information from transcription to regulation of RNA 
function and turnover, and in protein synthesis, functions and degradation (4). 
 
2. CFTR deficiency and increased expression of NFκB 
CFTR dysfunction affects innate immune pathways, generating an imbalance in the 
inflammatory status in epithelia in favour of pro-inflammatory markers.  
Normal CFTR has been shown to stabilise several membrane receptor proteins involved in the 
inflammation signalling pathways. It regulates TLR4- (Toll-Like Receptor 4, the membrane 
receptor of LPS, e.g. from Pseudomonas aeruginosa) mediated responses in secretory 
epithelia, by controlling the activation of Src (Rous Sarcoma virus oncogene Cellular 
homolog) tyrosine kinase. When CFTR is defective, the negative regulation of Src is lost and 
tyrosine kinase is free to target TLR4/NFκB and increase its response to endotoxins (5). It has 
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also been demonstrated that the dF508 CFTR mutation impairs osteoblast differentiation and 
function as a result of overactive NFκB and Wnt/β-catenin signalling (6-7). 
These observations support the view that CFTR acts as a tumor suppressor gene. RNA 
sequencing analyses of CFTR-deficient intestinal tumors confirmed an altered 
proinflammatory gene expression profile in normal CFTR-deficient tissues as well as in 
CFTR-deficient tumors (8). In the latter, CFTR deficiency results in upregulation of numerous 
proinflammatory chemokines, cytokines and their receptors, and members of the NFκB 
signalling pathway. 
 
3. From NFκB increased activity to development of cancer 
It has been suggested that NFκB, a hallmark of inflammatory responses that is frequently 
detected in tumors, may constitute a link between inflammation and cancer (9). Evidence is 
accumulating in favour of NFκB acting through its control of the apotosis/autophagy balance. 
Apoptosis is the broadly recognised mechanism of programmed cell death. Autophagy is a 
lysosomal process in which cytoplasmic constituents such as proteins, lipids, and organelles 
are degraded (10). It is activated in many situations of cell stress. It is a pivotal regulator of 
several important physiological processes including development, cell survival, differentiation 
and senescence. Tight regulation of both the NFκB pathway and that of the autophagy process 
is essential to homeostasis. Deregulation of both of these is frequently observed in cancer 
cells and is associated with tumorigenesis and tumor cell resistance to cancer therapies (11). 
In the case of pancreas cancer, high-throughput technologies and accurate disease models now 
provide a comprehensive picture of the diverse molecular signalling pathways and cellular 
processes governing adenocarcinoma genesis. Central among these is oncogene KRAS, a 
mediator of cellular plasticity, metabolic reprogramming, and inflammatory and paracrine 
signalling required for tumor development and maintenance. Autophagy is proposed to be one 
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of the cellular mechanisms contributing to pancreatic carcinogenesis, particularly during 
initial stages in which the KRAS oncogene appears to play a key role. Pancreatic autophagy, 
induced during pancreatitis by the overexpression of VMP1 (Vacuole Membrane Protein 1), 
promotes the development of precancerous lesions when induced by the mutated KRAS (12). 
In addition, the treatment with chloroquine, an inhibitor of autophagic flux, reverses the 
effects of VMP1 in pancreatic cancer induced by the KRAS oncogene (13). 
 
In summary, the link between CF, chronic pancreatitis and pancreas adenocarcinoma is 
complex and still largely unresolved. It involves several pathways and factors that can 
possibly balance each other. Better understanding of interactions between the CFTR protein, 
other membrane proteins such as receptors, and cytoplasmic transduction cascades could help 
orient future investigations. The structure of CFTR itself is a challenge for further research 
and the way to light is full of pitfalls. 
 
Reference 
1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 26, 420, 6917:860-867. 
2. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory 
epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression 
in a human bronchial epithelial cell line. J Clin Invest. 1992; 89, 5:1478-1484. 
3. Dhooghe B, Noël S, Huaux F, Leal T. Lung inflammation in cystic fibrosis: pathogenesis 
and novel therapies. Clin Biochem. 2014; 47, 7-8:539-546. 
4. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. 
Mol Cancer. 2013; 12:86. 
5. Fiorotto R, Villani A, Kourtidis A, Scirpo R, Amenduni M, Geibel PJ, Cadamuro M, Spirli 
C, Anastasiadis PZ, Strazzabosco M. The cystic fibrosis transmembrane conductance 
85 
 
regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine 
kinase activity. Hepatology. 2016; 64, 6:2118-2134. 
6. Le Henaff C, Mansouri R, Modrowski D, Zarka M, Geoffroy V, Marty C, Tarantino N, 
Laplantine E, Marie PJ. Increased NF-κB Activity and Decreased Wnt/β-Catenin Signaling 
Mediate Reduced Osteoblast Differentiation and Function in ΔF508 Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) Mice. J Biol Chem. 2015; 290, 29:18009-
18017. 
7. Liu K, Zhang X, Zhang JT, Tsang LL, Jiang X, Chan HC. Defective CFTR-β-catenin 
interaction promotes NF-κB nuclear translocation and intestinal inflammation in cystic 
fibrosis. Oncotarget. 2016; 7, 39:64030-64042. 
8. Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, 
Abrahante J, Schumann A, Luczak T, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman 
RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT. CFTR 
is a tumor suppressor gene in murine and human intestinal cancer. Oncogene. 2016; 35, 
32:4179-4187. 
9. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, 
Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in 
inflammation-associated cancer. Nature. 2004; 431, 7007:461-466. 
10. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Curr Top 
Microbiol Immunol. 2009; 335:1-32. 
11. Trocoli A, Djavaheri-Mergny M. The complex interplay between autophagy and NF-κB 
signaling pathways in cancer cells. Am J Cancer Res. 2011; 1, 5:629-649. 
12. Loncle C, Molejon MI, Lac S, Tellechea JI, Lomberk G, Gramatica L, Fernandez Zapico 
MF, Dusetti N, Urrutia R, Iovanna JL. The pancreatitis-associated protein VMP1, a key 
86 
 
regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer 
initiation. Cell Death Dis. 2016; 7:e2295. 
13. Iovanna JL. Autophagy Induced during Pancreatitis Promotes KRAS-Dependent 
Transformation in the Pancreas. Front Oncol. 2016; 6:226. 
  
87 
 
ABPA in adulthood: a CFTR-related disorder 
 
1P Lebecque, 2X Pepermans, 3E Marchand, 1A Leonard, 2T Leal 
1Pediatric Pulmonology & Cystic Fibrosis Unit, Cliniques Universitaires St Luc Université de 
Louvain, Belgium; 2Department of Genetics, Université de Louvain, Cliniques St Luc, 
Brussels, Belgium; 3Department of Respiratory Diseases, Université de Louvain, Cliniques de 
Mont-Godinne, Yvoir, Belgium 
Thorax. 2011 Jun; 66(6):540-1. 
In 2009, Prof. P. Lebecque, then head of the clinical CF Centre at St Luc Hospital, revisited 
an earlier publication on frequencies of CFTR mutations in patients with Allergic 
Bronchopulmonary Aspergillosis (ABPA) (Chest; Marchand et al. 2001); this paper was 
based on a molecular method using a panel of 13 common CFTR mutations. At the time, the 
hypothesis was spreading in the scientific community of the possible existence of other, still 
undetected, CFTR mutations responsible for the ABPA phenotype. Accordingly, Prof. P 
Lebecque asked the department of Genetics to update the analysis, and I performed an up-to-
date complete CFTR screening in the same cohort of patients in order to obtain more accurate 
insight on the link between CF and ABPA. Therefore, the work has been designed to address 
the fourth objective of the thesis project, i.e., to better characterise the nature of CFTR 
mutations, by sequence analysis, in the same group of patients from the princeps paper. The 
results of the new study are described in the adjacent paper.  
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Conclusion 
This work contributes in several ways to a deeper understanding of the involvement of the 
CFTR gene in patients with CF and CF-related disorders and it sheds new light on the 
molecular diagnosis.  
A new diagnostic screening method, xTAG (Luminex; panel of 71 mutations), was validated 
for routine analysis compared to the INNO-LiPA® (Innogenetics; panel of 36 mutations), 
used as a reference. The robustness of the method was established by using DNA samples 
extracted from different biological matrices, including blood samples, blood spots from 
Guthrie cards, chorionic villi and amniotic fluid. In this way, reproducible and concording 
results were obtained on the Luminex platform from all DNA Innogenetics positive samples. 
The new method, which uses a large panel of 71 mutations more specially designed for 
patients of southern European origin, significantly increases the detection rate. Since 2009, 
the method has been routinely used in first-line molecular diagnosis in the Human Genetics 
Centre of the Cliniques universitaires St-Luc. 
A contribution to a better molecular diagnosis of CF was achieved in the Santa Fe province of 
central Argentina, which has never been studied before. In this province, studying mutations 
in the CFTR gene allowed us to answer two questions. First, in a country largely populated by 
immigrates from mediterranean origin, the nature and distribution of mutations largely 
reproduces that of the countries of origin. Second, specific mutations never observed before, 
c.2554dupT (p.Tyr852Leufs*44) and c.146T>C (p.Leu49Pro), were discovered. We raise the 
hypothesis that they may be of aborigenic origin. As a result of the study, a new panel of 21 
mutations, better adapted locally, was proposed to replace the European panel presently used 
for the routine first line molecular diagnosis of classical CF in children. 
92 
 
Our work also contributed to a better understanding of the correlation between phenotype and 
genotype with a retrospective study of the effects of mutations in the PRSS1, CFTR or 
SPINK1 genes on the severity of sporadic idiopathic pancreatitis.  The results showed that 
clinical and morphological parameters were similar in patients carrying mutations in one of 
the three genes as in non-carriers, except for the age of pancreatic disease onset. However, a 
significantly higher occurrence of pancreas cancer was observed in the mutated group, 
particularly in patients carrying mutations in the CFTR gene. We therefore suggest that some 
CFTR variants present a risk factor for pancreatic cancer. 
A better understanding of the role of the CFTR gene in a specific pathology was provided by 
updating the molecular analysis of the CFTR gene in patients with allergic bronchopulmonary 
aspergillosis syndrome (ABPA). To this end, samples from patients analysed in 2001 using a 
panel of 13 mutations were re-analysed in 2010 using complete exonic sequencing and large 
rearrangement screening. Compared to the first analysis, 8 cases were found carrying one 
CFTR mutation and 4 with two mutations. Thus, the study considerably extends previous 
findings by demonstrating a strong link between ABPA in adults and CFTR mutations and 
further enriches our knowledge of the phenotype-genotype relationship.   
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Perspectives: The molecular diagnosis of CF from past to future 
The story of the molecular diagnosis of CF begins in 1989 
The discovery of the CFTR gene and of the p.Phe508del mutation took place in 1989. It 
created the molecular diagnosis of CF as a new tool for clinicians. At the time, it was initially 
accepted that the molecular diagnosis of CF was completely understood, with a single gene, a 
single protein and a single mutation, p.Phe508del, and the task of the molecular geneticist 
seemed simple. The evolution over the next two decades was by no means anticipated. I plan 
to give here an overview of the evolution of the molecular genetics, in parallel with the 
difficulties of the molecular diagnosis of the CFTR gene (patients with CF and CF-related 
disorders). 
In the early 90’s, the molecular diagnosis of the principal mutation, p.Phe508del, used a 
simple PCR with high resolution electrophoresis to detect deletion of the three base pairs. At 
the same time, a few additional mutations were identified using restriction enzymes. At the 
time, the best available technique was the Sanger sequencing method, which was very 
expensive and labour intensive (at least two weeks for only 200bp of length), and as all 
radioisotope-based methods, it used hazardous radioactive reagents. The development of the 
fluorescence method replaced the use of radioactive reagents, simultaneously reducing the 
technician time and allowing sequencing 500bp segments. A major advantage of the new 
method was the possibility to analyse an entire exon and to discriminate several mutations of 
different types, such as the p.Ile507del mutation which gave the same delta of 3bp as the 
p.Phe508del in the electrophoresis. Another advantage was that the method avoided 
uncertainties associated to the use of restriction enzymes, for example sufficient enzyme 
activity to discriminate mutated homozygous from heterozygous. 
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Ten years later 
At the end of the 90’s, a large number of mutations had been discovered in the CFTR gene. 
The most frequent one, p.Phe508del, was found in 40 to 95% of CF alleles in different 
European populations, and in the second position came a small group of mutations with 
frequencies between 1 and 5% of CF alleles. A third large group included rare local 
mutations, with frequencies less than 1%. A strategy of molecular diagnosis was then adopted 
(see, for example, European last best practice) (1), in which a panel of know mutations was 
defined; initially, it contained 13 mutations present regionally in high proportions and it was 
progressively extended to 71 mutations. The first paper presented above shows an application 
of this approach. An example of regional diversity in a given country is the distribution in 
France (2). Some regions, mainly outside Europe, have not been studied yet, and their local 
distributions are unknown. In my second paper above, I present the results of my study of 
distribution of mutations in the Santa Fe province of central Argentina, which had never been 
studied. In the study, I identified a small group of specific mutations present in high 
proportions, justifying development of a local panel of mutations.  
Despite the discovery of more local mutations, the task of the molecular geneticist, which 
seemed initially simple, became substantially more complicated and a source of frustration 
due to the impossible task of satisfying the demands of clinicians ("Please, find two 
mutations!"). As a matter of facts, identifying one particular mutation in a patient required 
heavy logistics and time, making it practically impossible to implement. 
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In the early 2000’s 
At the beginning of the years 2000, the cost of reagents decreased drastically, allowing 
automation of the Sanger sequencing method with a much higher throughput in diagnostic 
laboratories. It became possible to sequence the complete coding DNA sequence (CDS) of the 
CFTR gene nowadays known as the second line of genetic diagnosis. In those days, for 
practical reasons, CF centers chose to give priority to the analysis of unsolved classical CF 
patients, and as a result, a large proportion of patients carrying two mutations was found. 
At about the same time, following the detection of copy number variations (CNV), the idea 
appeared in laboratories of molecular genetics that Sanger sequencing alone was not enough, 
and the need arose for a parallel study to detect patients with two complete pathogenic alleles 
of the CFTR gene. The introduction of the MLPA method (3), easy to apply in routine 
practice, induced large hopes to help patients with CF phenotype carrying no, or only one 
mutation. Unfortunately, the number of mutations with large rearrangements in the CFTR 
gene represented only 1-1.5% of patients (4). 
Despite the major technical advances, the problem remained of selecting the part of the gene 
to be sequenced due to the ever increasing number of mutations. As a consequence, the 
frustration of the molecular geneticist grew because no clear end of the analysis procedure 
could be defined. 
 
Around 2010 
In the years 2010, it was decided to explore other genes in cases of patients with a CF 
phenotype in whom no CFTR mutation had been found. One example of such genes is that of 
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the epithelial Na+ channel (ENaC) family (5). Despite a strong hope to find mutations, the 
number of unresolved cases remained very high (6). 
The most spectacular breakthrough came after 2008 with the development of the next 
generation sequencing (NGS) methods. The NGS strategy applied by the genetic laboratories 
consists in substituting the Sanger method for the complete CDS of the CFTR gene, thereby 
enormously increasing the number of samples analysed. For example, a trained technician can 
now process 50-100 patients in three days, which is more than the total number of new 
patients of a CF center in one year. However, implementing the methods requires solving 
great problems. The difficulty of the diagnostic laboratory is now to demonstrate locally high 
sensitivity, specificity, accuracy, robustness, …. of the NGS method in order to obtain the 
ISO15189 certification, following the guidelines of the International Organization for 
Standardization. (7-10). 
Despite the information gathered in exploring other genes, it remained necessary to deepen 
the knowledge of the CFTR gene, because the other genes had not given useful answers in the 
case of an apparently monogenic disease, and because analysis of the CFTR gene was 
unfinished, since introns had not been sequenced. This is still valid today in routine diagnosis, 
and the frustration of the molecular geneticist remains. 
 
The present situation in 2016 
Now, a new situation has appeared during the last years. On the one hand, highly efficient 
diagnostic methods are available at an affordable cost; on the other hand, ever increasing and 
complex mutations have been identified so that the results of the genetic analysis can no 
longer be simply interpreted, as will be further explained below. From an initial apparently 
simple situation of a monogenic disease, additional gene alleles, called modifier genes, have 
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been recognised which directly influence the severity of the CF phenotype (11). And as a 
consequence, so far, no consensus gene panel in relation with CF and CF-related disorders has 
been agreed at an international level.  
In parallel, another method, the genome-wide associated studies (GWAS), has been used, 
with the aim of identifying other loci, (12) but the new loci need more meta-analysis to 
confirm the involvement in this disease. A better categorisation of phenotypes in a parallel 
extensive database of "phenomics" constitutes a new challenge.  
These two factors contribute to slow down the application of the most recent methods to 
laboratory practice. 
Another difficulty comes from the increasingly frequent request from clinical departments for 
molecular diagnosis in the case of patients with phenotypes very closely related to classical 
CF, for example idiopathic pancreatitis and ABPA, as illustrated in the third and fourth papers 
above. These cases require resorting more and more frequently to a second line diagnosis, 
which is substantially more demanding, not only technically but also in time spent in the 
interpretation of complex alleles. Indeed, a grey zone broadens up between a deleterious 
mutation and a polymorphism, making a clear molecular diagnosis and the task of the 
molecular geneticist nearly impossible. 
However, everything is not as grey. The new very broad interconnected public human 
genome databases (1000genome, Exome ExAC, ncbi, ensembl, uscs, ...) give access to a new 
control population database at a world-wide scale. For example, when a new variant, never 
observed before locally, is found in an Asian patient, consulting the large database allows 
comparing the variant to an Asian population. If this variant is present in a proportion larger 
than 5% in the database, it can be considered as a common polymorphism. The limit of 5% 
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represents an international consensus because the most common CFTR mutation, the 
p.Phe508del, is present in 4% of Caucasians. 
A possible way of solving the difficulties related to the CFTR gene, as explained above, 
would be to sequence by NGS the complete gene, including introns. The problem does not lie 
in the technology but in the shear size of the gene. As a matter of fact, in a gene of 250,000 
bp, 250 variants can theoretically be expected, as it is well known that on average, one variant 
is present for every 1,000 bp, and the majority of them are present in the introns. More in 
vitro models are needed to reveal the influence of splicing (13,14). This, however, is not the 
final answer, because when a partial splicing defect is found in the in vitro model, the 
consequence in the ex-vivo model is not fully predictable. Furthermore, when two complex 
variants are found, it is not known if they are present in cis or in trans if the parents' genes 
have not been analyzed. If they are adjacent, their possible reciprocal influence is also not 
known. 
 
A view of the future by the molecular geneticist 
In summary, disappointing immense initial hopes, the molecular diagnosis has not resolved all 
cases, despite huge technical progresses over the last half century. It is even quite the 
contrary. In the context of CF, the new methods of gene analysis and the added loci have 
increased the detection rate by only about 1% while making the interpretation considerably 
more difficult. The molecular diagnosis in medicine is now, and will remain in a foreseeable 
future, but one diagnostic tool among others, such as IRT screening, sweat test, nasal potential 
difference test,… to help the CF center. From the point of view of the geneticist, in many 
hereditary diseases, improving the categorisation of phenotypes, in other words the selection 
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of cohorts, seems to be the starting point to move forward in the way toward a more accurate 
diagnosis.  
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Annexe 
Impact of MIF gene promoter polymorphism on F508del 
cystic fibrosis patients. 
Melotti P1, Mafficini A2, Lebecque P3, Ortombina M1, Leal T4, Pintani E1, Pepermans  
X5, Sorio C2, Assael BM1. 
1. Cystic Fibrosis Centre, University and Hospital Trust of Verona, Verona, Italy; 2. ARC-
NET Research Centre and Department of Pathology and Diagnostics, University and Hospital 
Trust of Verona, Verona, Italy; 3. Pediatric Pulmonology & Cystic Fibrosis Unit, Universite´ 
Catholique de Louvain, Brussels, Belgium; 4. Louvain Centre for Toxicology and Applied 
Pharmacology, Universite´ Catholique de Louvain, Brussels, Belgium; 5. Centre for Human 
Genetics; Universite´ Catholique de Louvain, Brussels, Belgium. 
PLoS One. 2014 Dec 12; 9(12):e114274. 
This annexe includes a contribution I co-authored during my PhD programme. As a molecular 
geneticist, I took part in this collaborative work designed to try to determine if a 
polymorphism, 5-repeat allele displaying lower promoter activity, of the Macrophage 
migration Inhibitory Factor (MIF) is associated with disease severity in a group of Cystic 
Fibrosis patients homozygous for F508del CFTR mutation. Patients have been selected in two 
CF centers in Brussels and in Verona (Italy).  
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Résumé 
Un large spectre de plus de 2000 mutations CFTR ont été associées à un phénotype clinique 
très variable de la mucoviscidose. Dans ce travail, nous avons analysé le spectre des 
mutations du gène CFTR chez des patients atteints de mucoviscidose et dans les troubles 
associés à la mucoviscidose. Le projet vise spécifiquement à étudier les points suivants: 
1) Validation d'une nouvelle méthode de dépistage xTAG (Luminex, panel de 71 mutations), 
pour l'analyse de routine par rapport à l'INNO-LiPA® (Innogenetics, panel de 36 mutations), 
utilisé comme référence. Des résultats reproductibles et concordants ont été obtenus sur la 
plate-forme Luminex à partir d'échantillons ADN Innogenetics positifs utilisant de l'ADN 
extrait de différentes matrices biologiques, y compris des échantillons de sang, des taches de 
sang de cartes Guthrie, des villosités chorioniques et du liquide amniotique. Le nouveau panel 
augmente significativement le taux de détection pour les patients d'origine sud-européenne. 
2) Etude des fréquences des mutations du CFTR dans le centre de l'Argentine, dans la 
province de Santa Fe, qui n'a jamais été caractérisée. Une cohorte de 83 patients sur une 
sélection locale initiale de 121 a été analysée. Les résultats ont été combinés avec ceux d'une 
étude précédente de la province voisine de Cordoba, aboutissant à la proposition d'un panel 
unique de 21 mutations du CFTR pour un diagnostic moléculaire de première ligne au centre 
de l’Argentine. 
3) Analyse des effets des mutations dans les gènes PRSS1, CFTR ou SPINK1 sur la gravité de 
la pancréatite idiopathique sporadique. Une cohorte rétrospective de 68 patients porteurs de 
mutations dans ces gènes a été comparée à une cohorte, pairée pour l'âge et le sexe, de 
patients atteints de pancréatite idiopathique avec des tests génétiques négatifs. Les 
caractéristiques cliniques et morphologiques des patients ont été prises en compte dans 
l'analyse. Les paramètres cliniques étaient similaires dans les deux cohortes, à l'exception de 
l'âge d'apparition de la maladie pancréatique. Une augmentation significative du cancer du 
pancréas a été observée dans le groupe des patients porteurs de mutations, en particulier dans 
le gène CFTR. Nous suggérons donc que les variants de CFTR présentent un facteur de risque 
pour le cancer du pancréas. 
4) Mise à jour de l'analyse moléculaire du gène CFTR dans une cohorte de patients porteurs 
d'un syndrome d'aspergillose bronchopulmonaire allergique (ABPA). Les échantillons de 18 
patients précédemment analysés à l'aide d'un panel de 13 mutations et rapportés dans un 
article publié en 2001 ont été ré-analysés en 2010 en utilisant le séquençage complet des 
exons. Comparativement à la première analyse, 8 cas ont été trouvés porteurs d'une mutation 
CFTR et 4 de deux mutations. L'étude a considérablement étendu les résultats précédents en 
démontrant une forte relation entre ABPA chez les adultes et mutations du CFTR. 
Au total, ces études contribuent à jeter un éclairage nouveau sur le diagnostic moléculaire du 
gène CFTR dans les cas de patients atteints de mucoviscidose et de syndromes associés à la 
mucoviscidose. 
 
